ClinicalTrials.gg
CompletedNCT01998906Updated Oct 28, 2014Results posted

A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer

A Phase 3 interventional study of Trastuzumab and Doxorubicin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 36 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-28.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
56th of 366
330 · median 61
Started
2002
with 10 others
Phase 3
60 of 374
3 open now
Registered
212th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 56th largest by enrollment of the 366 interventional ones that give a count, is one of 11 that started in 2002, is one of 60 in phase 3, and was the 212th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will assess the efficacy and safety of adding Herceptin to a paclitaxel-containing regimen followed by cyclophosphamide/methotrexate/fluorouracil (CMF) chemotherapy in women with locally advanced breast cancer and HER2/c-erbB-2 gene amplification. In a parallel observational study patients with HER2-negative disease will receive the same chemotherapy without Herceptin.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients, >=18 years of age, with locally advanced breast cancer.

Exclusion criteria

Exclusion Criteria:

  • previous therapy for any invasive .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    HER-2+ Trastuzumab, Doxorubicin/Paclitaxel/CMF

    Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m\^2), IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m\^2, IV; methotrexate 40 mg/m\^2, IV; and 5-fluorouracil 600 mg/m\^2, IV, on Day 1 of Cycles 8 through 10.

    Drug: Trastuzumab · Drug: Doxorubicin · Drug: Paclitaxel · Drug: CMF

  • Active comparator
    HER-2+ Doxorubicin/Paclitaxel/CMF

    Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m\^2, IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.

    Drug: Doxorubicin · Drug: Paclitaxel · Drug: CMF

  • Active comparator
    HER-2- Doxorubicin/Paclitaxel/CMF

    Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m\^2, IV, and paclitaxel 150 mg/m\^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m\^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.

    Drug: Doxorubicin · Drug: Paclitaxel · Drug: CMF

Interventions

  • 8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17

    Also known as: Herceptin

  • 60 mg/m2 IV on Day 1 of Cycles 1 through 3

  • 150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7

  • DrugCMF

    CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10

06

What researchers measure

Primary outcomes

  1. Event-Free Survival (EFS) - Percentage of Participants With an Event

    EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause.

    Time frame: Baseline (BL), Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

  2. Event-Free Survival

    The median time, in months, between randomization and date of documented occurrence of an EFS event.

    Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

  3. Percentage of Participants Event Free at 1 Year

    Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

  4. Percentage of Participants Event Free at 2 Years

    Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

  5. Percentage of Participants Event Free at 3 Years

    Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

Secondary outcomes

  1. Percentage of Participants With Breast Pathological Complete Response (bpCR)

    bpCR was defined as an absence of any invasive cancer cell of the primary tumor at the time of major surgery after neoadjuvant chemotherapy with and without trastuzumab.

    Time frame: BL, Day 1 of Cycles 1-10 (pre-surgery)

  2. Percentage of Participants With Total Pathological Complete Response (tpCR)

    tpCR was defined as a determination of bpCR and an absence of positive axillary nodes on pathology.

    Time frame: BL, Day 1 of Cycles 1-10 (pre-surgery)

  3. Percentage of Participants Achieving Either Complete Response (CR) or Partial Response (PR) According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria

    Assessments were made based on objective tumor measurements of the lesions as recorded in the case report form. In inflammatory cancer, progressive disease (PD) was defined as progression of any of the 2 signs of breast edema and erythema. In non-inflammatory cancer, PD was concluded if either the investigator judged the participant as having progressed at any time prior to surgery, or there was at least a 20% increase in the sum of target lesions (TLs), any new lesion, or clear progression of any nontarget lesion (NTLs). Clear progression of any NTL was defined as at least a 20% increase in the sum of NTLs compared to BL. PR was defined as at least a 30% decrease from BL in the sum of the longest diameter of TLs. CR was defined as no PD as assessed by the investigator and complete disappearance of all lesions.

    Time frame: BL, Presurgery: Day 1 of Cycles 1-10

  4. Overall Survival (OS) - Percentage of Participants With an Event

    OS was defined as the time from the date of randomization to the date of the death due to any cause.

    Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

  5. Overall Survival

    OS was defined as the time from the date of randomization to the date of the death due to any cause.

    Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

  6. Percentage of Participants Surviving at 1 Year

    Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

  7. Percentage of Participants Surviving at 2 Years

    Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

  8. Percentage of Participants Surviving at 3 Years

    Time frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter

07

Results

Posted Oct 28, 2014

Participant flow

Participant flow — Overall Study
MilestoneHER2+ Trastuzumab/Doxorubicin/Paclitaxel/CMF (HER2+TC)HER2+ Doxorubicin/Paclitaxel/CMF (HER2+C)HER2- Doxorubicin/Paclitaxel/CMF (HER2-C)
Started11511699
Completed121
Not completed11411498
Withdrew: Participants ongoing in follow-up776058
Withdrew: Death213017
Withdrew: Lack of efficacy1098
Withdrew: Failure to return024
Withdrew: Violation of selection criteria001
Withdrew: Withdrawal by subject143
Withdrew: Administrative/other213
Withdrew: Other384

Outcome measures

PrimaryEvent-Free Survival (EFS) - Percentage of Participants With an Event

EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause.

Time frame:
Baseline (BL), Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Number · percentage of participants
Event-Free Survival (EFS) - Percentage of Participants With an Event
percentage of participantsHER2+ TCHER2+ CHER2- C
Event-Free Survival (EFS) - Percentage of Participants With an Event40.0 (47.7 to NA)50.9 (24.1 to NA)42.4 (57.7 to NA)
SecondaryPercentage of Participants With Breast Pathological Complete Response (bpCR)

bpCR was defined as an absence of any invasive cancer cell of the primary tumor at the time of major surgery after neoadjuvant chemotherapy with and without trastuzumab.

Time frame:
BL, Day 1 of Cycles 1-10 (pre-surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With Breast Pathological Complete Response (bpCR)
percentage of participantsHER2+ TCHER2+ CHER2- C
Percentage of Participants With Breast Pathological Complete Response (bpCR)44.3 (35.1 to 53.9)26.7 (18.9 to 35.7)19.2 (12.0 to 28.3)
Statistical analysis
  • HER2+ TC vs HER2+ C · Chi-squared · p = 0.0051 · Mean difference (final values): 17.6 · 95% CI 5.0 to 30.2
SecondaryPercentage of Participants With Total Pathological Complete Response (tpCR)

tpCR was defined as a determination of bpCR and an absence of positive axillary nodes on pathology.

Time frame:
BL, Day 1 of Cycles 1-10 (pre-surgery)
Reported as:
Number · percentage of participants
Percentage of Participants With Total Pathological Complete Response (tpCR)
percentage of participantsHER2+ TCHER2+ CHER2- C
Percentage of Participants With Total Pathological Complete Response (tpCR)40.0 (31.0 to 49.6)20.7 (13.7 to 29.2)18.2 (11.1 to 27.2)
Statistical analysis
  • HER2+ TC vs HER2+ C · Chi-squared · p = 0.0014 · Mean difference (final values): 19.3 · 95% CI 7.2 to 31.4
SecondaryPercentage of Participants Achieving Either Complete Response (CR) or Partial Response (PR) According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria

Assessments were made based on objective tumor measurements of the lesions as recorded in the case report form. In inflammatory cancer, progressive disease (PD) was defined as progression of any of the 2 signs of breast edema and erythema. In non-inflammatory cancer, PD was concluded if either the investigator judged the participant as having progressed at any time prior to surgery, or there was at least a 20% increase in the sum of target lesions (TLs), any new lesion, or clear progression of any nontarget lesion (NTLs). Clear progression of any NTL was defined as at least a 20% increase in the sum of NTLs compared to BL. PR was defined as at least a 30% decrease from BL in the sum of the longest diameter of TLs. CR was defined as no PD as assessed by the investigator and complete disappearance of all lesions.

Time frame:
BL, Presurgery: Day 1 of Cycles 1-10
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Either Complete Response (CR) or Partial Response (PR) According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
percentage of participantsHER2+ TCHER2+ CHER2- C
Percentage of Participants Achieving Either Complete Response (CR) or Partial Response (PR) According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) Criteria72.7 (63.4 to 80.8)66.4 (56.6 to 75.2)65.6 (55.2 to 75.0)
Statistical analysis
  • HER2+ TC vs HER2+ C · Chi-squared · p = 0.3077 · Mean difference (final values): 6.4 · 95% CI -6.4 to 19.1
SecondaryOverall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the date of randomization to the date of the death due to any cause.

Time frame:
BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants With an Event
percentage of participantsHER2+ TCHER2+ CHER2- C
Overall Survival (OS) - Percentage of Participants With an Event19.1 (NA to NA)28.4 (58.2 to NA)21.2 (NA to NA)
PrimaryEvent-Free Survival

The median time, in months, between randomization and date of documented occurrence of an EFS event.

Time frame:
BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Median · months
Event-Free Survival
monthsHER2+ TCHER2+ CHER2- C
Event-Free SurvivalNA (47.7 to NA)43.6 (24.1 to NA)64.5 (57.7 to NA)
Statistical analysis
  • HER2+ TC vs HER2+ C · Log Rank · p = 0.0275 · Hazard ratio (hr): 0.65 · 95% CI 0.44 to 0.96
PrimaryPercentage of Participants Event Free at 1 Year
Time frame:
BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Number · percentage of participants
Percentage of Participants Event Free at 1 Year
percentage of participantsHER2+ TCHER2+ CHER2- C
Percentage of Participants Event Free at 1 Year89 (84 to 95)82 (74 to 89)80 (73 to 88)
SecondaryOverall Survival

OS was defined as the time from the date of randomization to the date of the death due to any cause.

Time frame:
BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Median · months
Overall Survival
monthsHER2+ TCHER2+ CHER2- C
Overall SurvivalNA (NA to NA)NA (58.2 to NA)NA (NA to NA)
Statistical analysis
  • HER2+ TC vs HER2+ C · Log Rank · p = 0.0555 · Hazard ratio (hr): 0.59 · 95% CI 0.35 to 1.02
SecondaryPercentage of Participants Surviving at 1 Year
Time frame:
BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Number · percentage of participants
Percentage of Participants Surviving at 1 Year
percentage of participantsHER2+ TCHER2+ CHER2- C
Percentage of Participants Surviving at 1 Year100 (100 to 100)99 (97 to 100)97 (93 to 100)
PrimaryPercentage of Participants Event Free at 2 Years
Time frame:
BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Number · percentage of participants
Percentage of Participants Event Free at 2 Years
percentage of participantsHER2+ TCHER2+ CHER2- C
Percentage of Participants Event Free at 2 Years73 (64 to 81)61 (51 to 70)69 (60 to 78)
SecondaryPercentage of Participants Surviving at 2 Years
Time frame:
BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Number · percentage of participants
Percentage of Participants Surviving at 2 Years
percentage of participantsHER2+ TCHER2+ CHER2- C
Percentage of Participants Surviving at 2 Years95 (91 to 99)88 (82 to 94)90 (83 to 96)
PrimaryPercentage of Participants Event Free at 3 Years
Time frame:
BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Number · percentage of participants
Percentage of Participants Event Free at 3 Years
percentage of participantsHER2+ TCHER2+ CHER2- C
Percentage of Participants Event Free at 3 Years65 (56 to 74)52 (43 to 62)63 (53 to 72)
SecondaryPercentage of Participants Surviving at 3 Years
Time frame:
BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter
Reported as:
Number · percentage of participants
Percentage of Participants Surviving at 3 Years
percentage of participantsHER2+ TCHER2+ CHER2- C
Percentage of Participants Surviving at 3 Years85 (79 to 92)78 (70 to 86)85 (78 to 92)

Adverse events

Collected over BL, presurgery treatment Cycles 1-10, postsurgery Cycles 1-17, every 6 months thereafter for up to 60 months; yearly thereafter until primary analysis has taken place, after which serious adverse events were collected only if treatment related.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HER2+ TC—18/115 (15.7%)113/115 (98.3%)
HER2+ C—8/112 (7.1%)112/112 (100%)
HER2- C—9/99 (9.1%)98/99 (99%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventHER2+ TCHER2+ CHER2- C
Febrile neutropeniaBlood and lymphatic system disorders7/1153/1123/99
Deep vein thrombosisVascular disorders0/1153/1120/99
PyrexiaGeneral disorders3/1150/1120/99
NeutropeniaBlood and lymphatic system disorders1/1152/1120/99
DiarrhoeaGastrointestinal disorders0/1152/1120/99
NauseaGastrointestinal disorders0/1152/1120/99
PneumoniaInfections and infestations2/1150/1121/99
Ejection fraction decreasedInvestigations2/1150/1120/99
StomatitisGastrointestinal disorders0/1151/1121/99
Herpes zosterInfections and infestations0/1150/1121/99
Most frequent other events
Showing 10 of 64
Most frequent other events
EventHER2+ TCHER2+ CHER2- C
AlopeciaSkin and subcutaneous tissue disorders91/11587/11290/99
NauseaGastrointestinal disorders88/11588/11270/99
AstheniaGeneral disorders52/11558/11232/99
VomitingGastrointestinal disorders54/11552/11236/99
StomatitisGastrointestinal disorders46/11544/11221/99
MyalgiaMusculoskeletal and connective tissue disorders35/11525/11231/99
DiarrhoeaGastrointestinal disorders35/11532/11218/99
ConjunctivitisEye disorders34/11522/1127/99
ArthralgiaMusculoskeletal and connective tissue disorders34/11526/11219/99
ParaesthesiaNervous system disorders22/11529/11222/99

Baseline characteristics

Safety population: all participants who were randomized for the main study or registered for the observational parallel study and who received study medication at least once. Groups were analyzed as randomized/registered. Age was missing for 1 participant in the HER2+ TC treatment group.

Age, Continuous
Age, Continuous(years)HER2+ TCHER2+ CHER2- CTotal
Mean50.2 ± 9.7852.3 ± 10.9750.6 ± 10.4651.0 ± 10.42
Sex: Female, Male
Sex: Female, Male(Participants)HER2+ TCHER2+ CHER2- CTotal
Female11511299326
Male0000
08

Study locations

36 sites
  • Wien, 1090, Austria
  • Muenchen, 80637, Germany
  • Bologna, Emilia-Romagna 40138, Italy
  • Carpi, Emilia-Romagna 41012, Italy
  • Udine, Friuli-Venezia Giulia 33100, Italy
  • Milano, Lombardia 20133, Italy
  • Pavia, Lombardia 27100, Italy
  • Varese, Lombardia 21100, Italy
  • San Giovanni Rotondo, Puglia 71013, Italy
  • Sassari, Sardegna 07100, Italy
  • Pisa, Toscana 56100, Italy
  • Trento, Trentino-Alto Adige 38100, Italy
  • Bellunoi, Veneto 32100, Italy
  • Castelfranco Veneto, Veneto 31033, Italy
  • Mirano, Veneto 30035, Italy
  • Santorso, Veneto 36014, Italy
  • Vicenza, Veneto 36100, Italy
  • Lisboa, 1099-023, Portugal
  • Kazan, 420029, Russian Federation
  • Moscow, 107005, Russian Federation
  • Moscow, 115478, Russian Federation
  • Moscow, 117837, Russian Federation
  • Moscow, 129128, Russian Federation
  • Saint-Petersburg, 197758, Russian Federation
  • St Petersburg, 197022, Russian Federation
  • Terrassa, Barcelona 08221, Spain
  • Jerez de La Frontera, Cadiz 11407, Spain
  • San Sebastian, Guipuzcoa 20080, Spain
  • Barcelona, 08022, Spain
  • Barcelona, 08035, Spain
  • Barcelona, 08041, Spain
  • Barcelona, 08907, Spain
  • Madrid, 28041, Spain
  • Valencia, 46009, Spain
  • Valencia, 46010, Spain
  • Zaragoza, 50009, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2002, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2013
First posted
Dec 2, 2013
Start
May 2002
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Oct 28, 2014
Last update
Oct 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01998906
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 2, 2013
Start date
May 2002
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Oct 28, 2014
Last update
Oct 28, 2014

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion